Rapid Formation of Novel Targeted Prodrugs: Based on validated active substances and targets, the platform can quickly generate novel targeted prodrugs that offer significant improvements in pharmacokinetics/pharmacodynamics or safety. It efficiently produces candidate compounds with high clinical development value.

High druggability with robust patent protection to enable accelerated development cycles, reduced costs, and sustained competitive advantage.

Effective chemical structure modifications are used to improve various drug properties, including physicochemical characteristics, delivery and transport efficiency, enzyme selectivity, and compound stability. AI technology is employed to enhance precision and efficiency.

The platform achieves targeted delivery to specific disease-affected organs. This not only ensures therapeutic efficacy but also provides better safety profiles, achieving an optimal balance between efficacy and safety.